OverviewSuggest Edit

Indivior develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The Company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue and CNS disorders/schizophrenia. It markets and promotes Suboxone sublingual film, Suboxone sublingual tablet and Subutex sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex and Buprenex.

HQRichmond, VA, US
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2017)934
Job Openings106
Revenue (FY, 2018)£793.9 M(-3%)
Share Price (Oct 2021)£2.3
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Indivior

Howard Pien

Howard Pien

Non-executive Chairman
Mark Crossley

Mark Crossley

Chief Executive Officer
Shaun Thaxter

Shaun Thaxter

Chief Executive Officer, Director
Jason Thompson

Jason Thompson

Vice President, Investor Relations
Jerome Lande

Jerome Lande

Non-Executive Director
Peter Bains

Peter Bains

Non-Executive Director
Show more

Indivior Office Locations

Indivior has offices in Richmond, Baltimore, Chicago, Cleveland and in 10 other locations
Richmond, VA, US (HQ)
10710 Midlothian Turnpike #430
Baltimore, MD, US
Baltimore, MD, USA
Chicago, IL, US
Chicago, IL, USA
Cleveland, OH, US
Cleveland, OH, USA
Dayton, OH, US
Dayton, OH, USA
Fort Collins, CO, US
Fort Collins, CO, USA
Show all (14)

Indivior Financials and Metrics

Indivior Revenue

Embed Graph
View revenue for all periods
Indivior's revenue was reported to be £793.9 m in FY, 2018

Revenue (FY, 2018)


Gross profit (FY, 2018)


Gross profit margin (FY, 2018), %


Net income (FY, 2018)


EBITDA (FY, 2018)


EBIT (FY, 2018)


Market capitalization (15-Oct-2021)


Closing stock price (15-Oct-2021)


Cash (31-Dec-2018)

Indivior's current market capitalization is £1.7 b.
GBPFY, 2015FY, 2016FY, 2017FY, 2018



Revenue growth, %


Cost of goods sold


Gross profit

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable




Current Assets

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income


Cash From Operating Activities


Dividends Paid


Cash From Financing Activities

GBPFY, 2013

Financial Leverage

-6.5 x
Show all financial metrics

Indivior Operating Metrics

Indivior's Clinical Programs was reported to be 12 in FY, 2016.
FY, 2016

Clinical Programs


Phase I Trials Products


Phase II Trials Products


Phase III Trials Products

Show all operating metrics

Indivior Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Indivior Online and Social Media Presence

Embed Graph

Indivior News and Updates

The Rosen Law Firm, P.A. Announces Proposed Securities Class Action Settlement on Behalf of Purchasers of Indivior PLC securities – INVVY

NEWARK, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the District of New Jersey has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of Indivior PLC securities …

Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding

IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022

Indivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading Asset Targeting Cannabis-Related Disorders

RICHMOND, Va., June 8, 2021 /PRNewswire/ -- Indivior PLC, (LON: INDV) today announced that it is extending its leadership position in substance use disorder ("SUD") treatment by expanding into the under treated cannabis-related disorders, including cannabis use disorder ("CUD") and...

Indivior Announces Availability of Third Quarter and Nine Months 2020 Results

SLOUGH, England, and RICHMOND, Va., Oct. 29, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that financial results for the third quarter and nine months period ended September 30, 2020, including the press release and investor supplement, are now available on the Group's...

Indivior Takes Strategic Alignment Actions

SLOUGH, United Kingdom and RICHMOND, Virginia, Sept. 24, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the Group's strategic priorities. These actions further consider...

Indivior First Half and Second Quarter 2020 Results Now Available; Conference Call With Leadership Today

SLOUGH, United Kingdom, and RICHMOND, Va., July 30, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half and second quarter 2020 results press release is now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section...
Show more

Indivior Frequently Asked Questions

  • Who are Indivior key executives?

    Indivior's key executives are Howard Pien, Mark Crossley and Shaun Thaxter.

  • How many employees does Indivior have?

    Indivior has 934 employees.

  • What is Indivior revenue?

    Latest Indivior annual revenue is £793.9 m.

  • What is Indivior revenue per employee?

    Latest Indivior revenue per employee is £850 k.

  • Who are Indivior competitors?

    Competitors of Indivior include Procaps, Bachem Holding and EVA Pharma.

  • Where is Indivior headquarters?

    Indivior headquarters is located at 10710 Midlothian Turnpike #430, Richmond.

  • Where are Indivior offices?

    Indivior has offices in Richmond, Baltimore, Chicago, Cleveland and in 10 other locations.

  • How many offices does Indivior have?

    Indivior has 14 offices.